Fear-themed digital media exposure and sleep regulatory sensitivity in school-aged children: preliminary observations toward a developmental PhenoSleep construct - Takeaways - MDSpire

Fear-themed digital media exposure and sleep regulatory sensitivity in school-aged children: preliminary observations toward a developmental PhenoSleep construct

  • By

  • Martina Gnazzo

  • Giuditta Bargiacchi

  • Eva Germanò

  • Agata Maltese

  • Lucia Parisi

  • Laura Firrigno

  • Michele Roccella

  • Giulia Spoto

  • Gabriella Di Rosa

  • Lidia Scifo

  • Beatrice Gallai

  • Davide Testa

  • Annamaria Maddalena Terracciano

  • Marco Carotenuto

  • May 22, 2026

  • 0 min

Share

  • 1

    Fear-themed digital media exposure in children may reveal individual differences in sleep regulatory sensitivity rather than causing direct psychopathology.

  • 2

    The study involved 132 children aged 5–11, divided into exposed and control groups, to assess the impact of fear-themed content on sleep regulation.

  • 3

    Exposed children exhibited higher total problems on the Child Behavior Checklist and sleep disturbance scores compared to the control group.

  • 4

    Engagement intensity with fear-themed content showed small positive associations with social, cognitive, and sleep-related measures in exposed children.

  • 5

    The PhenoSleep construct is introduced to describe developmental variability in sleep continuity and arousal modulation in response to emotionally intense stimuli.

Original Source(s)

Fear-themed digital media exposure and sleep regulatory sensitivity in school-aged children: preliminary observations toward a developmental PhenoSleep construct

  • by Martina Gnazzo, Giuditta Bargiacchi, Eva Germanò, Agata Maltese, Lucia Parisi, Laura Firrigno, Michele Roccella, Giulia Spoto, Gabriella Di Rosa, Lidia Scifo, Beatrice Gallai, Davide Testa, Annamaria Maddalena Terracciano, Marco Carotenuto

  • May 22, 2026

Related Content

Toward integrated sleep health: multimodal AI in Hang Hao Meng agent

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.